MIRO
Miromatrix Medical Inc. [MIRO] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
MIRO Stock Summary
In the News
MIRO Financial details
Company Rating
-
Market Cap
92.95M
Income
-27.12M
Revenue
958.03K
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
76
Optionable
No
Shortable
Yes
Earnings
29 Mar 2024
P/E
-3.41
Forward P/E
-
PEG
2.61
P/S
97.02
P/B
5.96
P/C
-
P/FCF
-3.79
Quick Ratio
3.25
Current Ratio
3.46
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.13
EPS next Y
-
EPS next Q
-
EPS this Y
11.54%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
31.22%
EPS Q/Q
-
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-116%
ROE
-119%
ROC
-1.54%
Gross Margin
48%
Oper. Margin
-2973%
Profit Margin
-2831%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.906-4.35
52W High
-
52W Low
-
RSI
79
Rel Volume
3.87
Avg Volume
163.02K
Volume
631.56K
Perf Week
0%
Perf Month
1.5%
Perf Quarter
-
Perf Half Y
192.24%
-
-
-
-
Beta
0.015
-
-
Volatility
0%, 0.02%
Prev Close
0%
Price
3.39
Change
0%
Company Profile
- Volume Average 163.02K
- Market Capitalization 92.95M
- Employee 76
- CEO Dr. Jeffrey James Ross Ph.D.
- Headquarters Eden Prairie,MN,US
- IPO Date 2021-06-24
-
Website
https://www.miromatrix.com 
Miromatrix Medical Inc., a life sciences company, develops a novel technology for bioengineering fully transplantable organs. Its proprietary technology is a platform that uses a two-step method of decellularization and recellularization designed to remove the porcine cells from the organs obtained from pigs and replace them with unmodified human cells. The company has collaborations with The Mayo Clinic, Mount Sinai Hospital, and The Texas Heart Institute. The company was formerly known as TayTech, Inc. Miromatrix Medical Inc. was incorporated in 2009 and is headquartered in Eden Prairie, Minnesota.
